Autopsy report · NCT04655573

A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer

“requested by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Duke University

Sponsor type

University, hospital or other

Conditions

Advanced Breast Cancer

Interventions

Breast Cancer Tumor Resection

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus
  “Sponsor request” (92% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (88% match in meaning)
• A Study to Evaluate ART101 in Adult Participants With Hypertension
  “At Sponsor's Request” (87% match in meaning)
• A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
  “Decided by sponsor” (74% match in meaning)
• Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
  “Sponsor related” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.